Past Event: Calgary Drug Trends Summit

November 02, 2016
Downtown Marriott Hotel, Calgary

Calgary Drug Trends Summit

Are you interested in learning about topics that will impact your drug plan?

Join us for the 2016 Calgary Drug Trends Summit.

This half-day event will provide the education and resources plan sponsors and plan advisors need to make the best decisions for their members. Attendees can look forward to presentations examining specific disease states and challenges; new drug treatment categories/offerings; and key drug trends that keep plan sponsors up at night.

Who Should Attend?

Employers responsible for drug plans, benefits, wellness, HR, corporate health; brokers, benefit consultants and advisors.

Am I Eligible?

The Calgary Drug Trends Summit is for plan sponsors, consultants and advisors. To determine if you are eligible, please email Lauren Harris, Conference Editor, Benefits Canada.

Price: $49 + TAX
.

Feel free to tweet us @BenCanMag or #drugtrends

Calgary Drug Trends Summit

November 2, 2016
Downtown Marriott Hotel, Calgary


7:00 - 7:55 a.m.
Breakfast and Registration



7:55 - 8:00 a.m.
Opening Remarks


8:00 - 8:30 a.m.
Private health insurance: A Prescription for Sustainability


Plan sponsors play a pivotal role in keeping Canada’s workforce healthy and productive. Today’s employers are challenged with finding cap space to ensure access to new medicines in the future amid overall rising health care premiums. We will take a closer look at the trends and challenges facing the private market and look at how plan sponsors can have a positive impact on the future sustainability of their private health insurance plans to ensure future access to new medicines important to the health and productivity of their employees.

Speaker:
Joe Farago, executive director, healthcare innovation, Innovative Medicines Canada

[Download the Presentation]



8:30 - 9:00 a.m.
The Unintended Consequences of Cost Containment

IBD (Inflammatory bowel disease) which includes Crohn’s disease and ulcerative colitis are financially burdensome on both employers and their employees. Dr. Yvette Leung will highlight to the audience what it’s like to live with IBD and how biologics provide significant value for payers and patients alike, both because of their clinical benefits as well as the comprehensive patient assistance programs associated with these therapies.

Speaker:
Dr. Yvette Leung, gastroenterologist, assistant clinical professor, University of Calgary (Participation made possible by Janssen)

[Download the Presentation]



9:00 - 9:30 a.m.
“The opioid crisis” – trends and considerations for benefit plans

Canada is facing an opioid crisis with increasing rates of addictions, overdoses and deaths attributed to both prescription and illicit opioids. Factors contributing to the crisis and the medications involved will be examined. A review of opioid trends in benefit plans, and considerations for plan sponsors will be discussed.

Speaker:
Margaret Wurzer, senior manager, benefits and product development, Alberta Blue Cross

[Download the Presentation]



9:30 - 10:00 a.m.
Networking Break



10:00 - 10:30 a.m.
Access to Treatments: A Patient Perspective

The importance of access to treatments (pharmaceutical and otherwise) while living with a chronic disease will be discussed from the perspective of a person who lives with rheumatoid arthritis. Further, her journey will be chronicled by the importance that benefits coverage has played as well as developing a collaborative relationship with her healthcare providers by effectively communicating outcomes that are important to patients.

Speaker:
Dawn Richards, science and patient consultant

[Download the Presentation]



10:30 - 11:00 a.m.

Catching a Tiger by the Tail: Insuring needed oncology therapies

Exciting breakthroughs in cancer research have led to new treatment options; improving survivorship and transforming some cancers into a chronic disease. Research is key, but it is only one element in helping patients live long and fulfilling lives. If we are to realize the promise of these new medications, we need to address the challenges to ensure that high-value treatments are integrated into routine practice in a thoughtful manner to ensure that patients receive the necessary treatments at the right time. This session will provide a physician’s perspective on public and private collaboration in the treatment of cancer, growing concerns of the oncology community, and how the employer plays a pivotal role in patient outcomes.

Speaker:
Dr. Alexander H.G. Paterson, medical oncologist, Department of Medicine Tom Baker Cancer Centre

[Contact for Presentation]

11:00 - 11:30 a.m.
The Benefits of Biosimilars for Benefit Programs

Biosimilar medicines present a significant opportunity to address the cost-effectiveness demands on drug benefit plans in Canada. They can significantly increase patient access to high quality treatments and improve health outcomes through appropriate earlier use of biologic medicines. Despite these benefits, the future of biosimilar medicines in Canada remains unclear. What can plan sponsors do to support their market acceptance and incentivize their reimbursement?

Speaker:
Jim Keon, president, Biosimilars Canada

[Download the Presentation]



11:30 a.m. - 12:00 p.m.

How patients really feel about Biosimilars

This presentation will discuss the findings from a survey with 300 Canadian patients about their perspectives on biosimilars, including safety, availability, use, monitoring and support issues. It will also provide an overview of discussions with patients representing various diseases that indicate some of the factors that influence acceptance and confidence.

Speaker:
Durhane Wong-Rieger, president and chief executive officer, Canadian Organization for Rare Disorders

[Download the Presentation]

12:00 p.m.
Closing Remarks

Calgary Drug Trends - Speakers

 

Joe Farago

Joe Farago

Joe Farago was hired in January 2016 as the executive director healthcare innovation for Innovative Medicines Canada, which represents Canada's innovative pharmaceutical industry. Farago is responsible for the private payer market. Shortly after joining the organization Farago identified the rapid changes and challenges taking place in the private payer space that impact future patient access. He has been responding by mobilizing resources to focus on bringing discussions and solutions to the stakeholder table that will ensure the sustainability of the private market insurance in Canada. Farago is leading the industries efforts in taking a more proactive approach to addressing today’s issue to ensure tomorrow's workforces in Canada have strong private market coverage best suited to meeting their needs. Over the last 27 years, Farago has acquired a vast knowledge of the Canadian Pharmaceutical and Specialty Biopharmaceutical markets. He has a wide range of experience in access, government affairs, sales, marketing and operations. Farago has had the opportunity to be part of establishing two organizations in the Canadian market from the ground up and brings a strong understand of market access success and organizational development. Farago started his pharmaceutical career with Servier Canada in 1989 until he entered the Plasma Protein Specialty market with CSL Limited in 2007 where he was instrumental in establishing and building the Canadian organization to a market leader. Farago attended Carleton University, graduating in 1989 with a BSc.

 



Jim Keon

Jim Keon

Jim Keon is President of Biosimilars Canada, the voice of Canada's biosimilar medicines industry. Keon graduated with an M.A. in Economics from Queen's University, and has more than 20 years' experience in the pharmaceutical sector. Keon was named the founding President of Biosimilars Canada in January 2015. He also serves as President of the Canadian Generic Pharmaceutical Association (CGPA). Prior to joining CGPA in 1994 he held senior positions in the federal government and was directly involved in international trade negotiations for NAFTA and the WTO, as well as Canada's inter-provincial trade negotiations. Keon is Past Chair of the International Generic and Biosimilar Medicines Association (IGBA), which is committed to promoting the interests of generic and biosimilar medicines around the world. He is currently Chair of the IGBA International Trade Committee.


 


 


Dr. Yvette Leung

Dr. Yvette Leung

Dr. Yvette Leung is a gastroenterologist and assistant clinical professor with the University of Calgary. Dr. Leung went to medical school at the University of Calgary and completed her medical residency at the University of British Columbia. She went on to complete her Gastroenterology Fellowship at the University of Calgary and an Advanced IBD Fellowship at the University of Chicago prior to becoming faculty as an Assistant Clinical Professor at the University of Calgary. She has recently moved to Vancouver, British Columbia. Her research interests include: pregnancy and IBD, impact of subclinical inflammation on perinatal outcomes, and the psychosocial impact of IBD on young adults.


 


 

Dr. Alexander Paterson

Dr. Alexander Paterson

Dr. Alexander Paterson trained at Edinburgh Medical School and in London (St. Bartholome's Hospital and Royal Marsden). He has completed clinical research in melanoma and gynecological malignancies; phase I/II and III clinical trials; research in breast cancer; research on natural history of breast cancer; and established and novel prognostic factors in breast cancer; patho-physiology and treatment of bone metastases; malignant hypercalcemia and its treatment; and prevention of bone metastases with bisphosphonates. He has also performed clinical research in palliative care medicine, prevention and treatment trials in breast cancer (with US based NSABP) and previously, research in autologous bone marrow transplantation. Tumor imaging radio-pharmaceuticals have also been included in his fields of research. He is on the Board of Directors of the NSABP and is Chair of NSABP B34 protocol and a Co-chair of the SWOG/NSABP intergroup bone metastasis prevention trial. Paterson was Chair of the Alberta Breast Cancer Programme 2002-2010 and is Chair of the Health Canada Oncology Therapies Scientific Advisory Committee. He is a clinical oncologist at the Tom Baker Cancer Centre and University of Calgary with a full-time practice mainly in patients with carcinoma of the breast. He teaches in the Physical Examination Course to medical students in the University of Calgary and writes a column for Alberta Doctors’ Digest on general topics.

 


 

Dawn Richards

Dawn Richards

Dawn Richards is a science and patient consultant, with a PhD in analytical chemistry. Her diagnosis with rheumatoid arthritis a decade ago instigated her career journey to combine her passion for science and make the most of her diagnosis. As a volunteer patient advocate, Richards is Vice President of the Canadian Arthritis Patient Alliance and a member of The BMJ’s Patient Panel Reviewers, and formerly the first Patient Advisor of the Canadian Medical Association’s Wait Time Alliance and member of CIHR’s Institute Advisory Board of the Institute of Musculoskeletal Health and Arthritis.

 

 


 

Dr. Durhane Wong-Rieger

Dr. Durhane Wong-Rieger

Dr. Durhane Wong-Rieger is president and chief executive officer of the Canadian Organization for Rare Disorders (the umbrella organization of patients and patient groups) and chair of the Consumer Advocare Network, a national network for patient engagement in healthcare policy and advocacy. She is also president and chief executive officer of the Institute for Optimizing Health Outcomes (providing training and direct service on health coaching and patient self-management). Internationally, Dr. Wong-Rieger is past-chair of the International Alliance of Patient Organizations, board member of Rare Disease International, member of Health Technology Assessment International Patient/Citizen Involvement Interest Group and member of the editorial board of The Patient-Patient Centred Outcomes Research. She is a certified health coach and licensed T-Trainer with the Stanford-based Living a Healthy Life with Chronic Conditions. Dr. Wong-Rieger has served on numerous health policy advisory committees and panels and is a member of the Patient Liaison Forum for the Canadian Drugs and Technologies in Health. Dr. Wong-Rieger has a PhD in psychology from McGill University and was professor at the University of Windsor, Canada from 1984-1999. She is married and has two children. She is a trainer and frequent lecturer and author of three books and many articles.






Margaret Wurzer

Margaret Wurzer

Margaret Wurzer is senior manager, benefits and product development with Alberta Blue Cross. She is currently responsible for overseeing product development as well as managing the drug benefit management area, responsible for providing support to Alberta Blue Cross’ Group and Individual divisions with all aspects of drug management. Wurzer has more than 22 years of experience at Alberta Blue Cross. In her previous role as Senior Manager of the Clinical Drug Services department, she was responsible for strategic planning of the department’s administration of its Special Authorization processes, clinical services, and for drug pricing for government, group, and individual drug plans.She holds a Master of Science degree in Pharmacy from the University of Saskatchewan and a Bachelor of Science degree in Pharmacy from the University of Alberta. She is a licensed clinical pharmacist with the Alberta College of Pharmacists.

 

 


For information on the conference, please contact Lauren Harris, Conference Editor, Benefits Canada

 

Calgary Marriott Downtown Hotel

The luxury Calgary Marriott Downtown Hotel features modern accommodations, exceptional service, and a prime location in the heart of the city. Our elegant guest rooms and suites successfully cater to both business and leisure travelers, with plush bedding, 37-inch flat-screen TVs, and Marriott's exclusive Plug-In panel technology. Additional amenities include high-speed Internet access and luxury bathroom amenities. Enjoy sweeping views of downtown Calgary and the Canadian Rockies throughout the hotel, thanks to natural lighting from floor-to-ceiling windows. Start your morning with breakfast in our onsite restaurant, or grab a cup of Starbucks® coffee to go. In the evening, unwind at our vibrant cocktail lounge. Planning an event in Calgary? We offer stylish and flexible event space and full catering services. And our convenient hotel location places Calgary's finest restaurants and shopping just steps from our door. Style and substance come together beautifully at the Calgary Marriott Downtown Hotel.

Calgary Marriott

110 9th Avenue SE  Calgary  Alberta  T2G 5A6  Canada 



(Click on link for map of the area)


Need more information on the venue or have questions about registration?

Contact experience manager, Wendy Morrison, at 416-764-3836